Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP

Keyphrases

• Multidrug Resistance Reversal 100%
• P-glycoprotein (P-gp) 100%
• Doxorubicin 100%
• Lipid Nanoparticles 100%
• Paclitaxel 100%
• Nanoparticles 66%
• Overexpressing 50%
• Calcein 33%
• IC50 Value 33%
• Paclitaxel Nanoparticles 33%
• Apoptosis 16%
• Cytotoxicity 16%
• Mitochondrial Membrane Potential 16%
• Tumor 16%
• Efflux 16%
• Anticancer Activity 16%
• Cell-based Assay 16%
• Taxol 16%
• Biological Mechanisms 16%
• Multidrug Resistance 16%
• ATP Depletion 16%
• Nude Mice 16%
• Cancer Cells 16%
• Nanoparticle Formulation 16%
• In Vitro Cells 16%
• Enhanced Uptake 16%
• Prolonged Retention 16%
• Efflux Inhibition 16%
• ATP Level 16%
• ATP Assay 16%
• Membrane Integrity 16%
• Drug Mechanism 16%
• PEGylated 16%
• Uptake Inhibition 16%
• P-glycoprotein Inhibitor 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenosine Triphosphate 100%
• Nanoparticle 100%
• Paclitaxel 100%
• P-Glycoprotein 100%
• Doxorubicin 100%
• Multidrug Resistance 100%
• Effusion 25%
• Calcein 25%
• IC50 25%
• Malignant Neoplasm 12%
• Neoplasm 12%
• Nude Mouse 12%
• Solid Lipid Nanoparticle 12%
• Cytotoxicity 12%